-transparent.png){kind=logo}
A total of 115 elderly patients (60-85 years of age) with DSM III diagnosis of major depressive episode were randomly assigned to 6 weeks of treatment with either mirtazapine, 15-45 mg/day, or amitriptyline, 30-90 mg/day. Efficacy was assessed biweekly, using the Hamilton Rating Scale for Depression (HRSD) and Montgomery and Asberg Depression Rating Scale (MADRS) as primary outcome variables. The treatment with both drugs resulted in a similar reduction of total HRDS and MADRS scores, with no statistically significant differences between treatment groups at any assessment point or at endpoint. Statistically significant differences favouring amitriptyline were present according to CGI-Global Improvement Scale at endpoint, HRDS cognitive disturbance factor at weeks 2, 4 and 6 and endpoint and retardation factor at week 6. Adverse events were reported by a similar number of patients in both treatment groups. Additional research is needed to assess further the efficacy and tolerability of mirtazapine among elderly depressed patients.
O J Høyberg, and
B Maragakis, and
J Mullin, and
D Norum, and
E Stordall, and
P Ekdahl, and
E Ose, and
K M Moksnes, and
C Sennef
January 2002,
The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry,
O J Høyberg, and
B Maragakis, and
J Mullin, and
D Norum, and
E Stordall, and
P Ekdahl, and
E Ose, and
K M Moksnes, and
C Sennef
December 1990,
The Journal of clinical psychiatry,
O J Høyberg, and
B Maragakis, and
J Mullin, and
D Norum, and
E Stordall, and
P Ekdahl, and
E Ose, and
K M Moksnes, and
C Sennef
January 1996,
Journal of psychopharmacology (Oxford, England),
O J Høyberg, and
B Maragakis, and
J Mullin, and
D Norum, and
E Stordall, and
P Ekdahl, and
E Ose, and
K M Moksnes, and
C Sennef
April 1980,
International journal of clinical pharmacology, therapy, and toxicology,
O J Høyberg, and
B Maragakis, and
J Mullin, and
D Norum, and
E Stordall, and
P Ekdahl, and
E Ose, and
K M Moksnes, and
C Sennef
January 1972,
Psychosomatics,
O J Høyberg, and
B Maragakis, and
J Mullin, and
D Norum, and
E Stordall, and
P Ekdahl, and
E Ose, and
K M Moksnes, and
C Sennef
June 1992,
International clinical psychopharmacology,
O J Høyberg, and
B Maragakis, and
J Mullin, and
D Norum, and
E Stordall, and
P Ekdahl, and
E Ose, and
K M Moksnes, and
C Sennef
May 1983,
The Journal of clinical psychiatry,
O J Høyberg, and
B Maragakis, and
J Mullin, and
D Norum, and
E Stordall, and
P Ekdahl, and
E Ose, and
K M Moksnes, and
C Sennef
May 1987,
Acta psychiatrica Scandinavica,
O J Høyberg, and
B Maragakis, and
J Mullin, and
D Norum, and
E Stordall, and
P Ekdahl, and
E Ose, and
K M Moksnes, and
C Sennef
January 1989,
Acta psychiatrica Scandinavica. Supplementum,
O J Høyberg, and
B Maragakis, and
J Mullin, and
D Norum, and
E Stordall, and
P Ekdahl, and
E Ose, and
K M Moksnes, and
C Sennef
June 1995,
Psychopharmacology,
